Psyence Biomedical Announces Initiation Of First Trial Site In Australia For Phase IIb Study Of Nature Derived Psilocybin As Potential Treatment For Adjustment Disorder In Palliative Care
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical, a NASDAQ-listed associate of Psyence Group, has initiated its first trial site in Australia for a Phase IIb study. The study focuses on using nature-derived psilocybin as a potential treatment for adjustment disorder in palliative care.
September 16, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomedical has initiated a Phase IIb study in Australia to explore psilocybin as a treatment for adjustment disorder in palliative care. This marks a significant step in their clinical research efforts.
The initiation of a Phase IIb trial is a critical step in drug development, indicating progress in Psyence Biomedical's research. This could positively impact investor sentiment and the stock price as it shows advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80